title: Prospects for subunit vaccines: Technology advances resulting in efficacious antigens requires matching advances in early clinical trial investment.
abstract: With the continued march of antimicrobial resistance, a renewed impetus for better vaccines has been heralded. Identification of potent subunit vaccines has been greatly facilitated by recent developments in reverse vaccinology and proteomics strategies. There are a range of antimicrobial resistant bacterial pathogens that could be targeted by potent vaccine antigens identified within the coming years. However, cost is a significant hurdle in progressing lead antigen candidates to clinical trials. In order for novel vaccine technologies to realize their clinical potential, there is a requirement to improve investment and incentives to expedite the development of vaccines that are apparently efficacious in preclinical trials.
authors: a Centre of Microbial Host Interactions , Institute of Technology Tallaght , Dublin , Ireland.
authors: Siobhán
authors: S
authors: McClean
mesh_terms: D000486:Allergy and Immunology / Q000639:trends*; D000941:Antigens / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D013678:Technology, Pharmaceutical / Q000639:trends*; D022223:Vaccines, Subunit / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D000941:Antigens; D022223:Vaccines, Subunit
keywords: clinical trials; proteomics; subunit vaccines; vaccine development; vaccinology